Evidence map›Paper›PMID 41910325›Full record

ArticleJournal of clinical microbiology2026

A cartridge-based assay for improved detection of multidrug-resistant

Paulami Rudra, Heta Parmar, Naranjargal Daivaa, Claire Tran, Anshika Narang, Simranjit Singh, Dhara Somaiya, Samarpita Roybardhan, Ritu Anwesa, Robert Reiss and 11 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Paulami Rudra *Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.ORCID 0009-0006-8980-2078
Heta Parmar *Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Naranjargal DaivaaDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Claire TranCepheid Inc., Sunnyvale, California, USA.
Anshika NarangCepheid Inc., Sunnyvale, California, USA.
Simranjit SinghCepheid Inc., Sunnyvale, California, USA.
Dhara SomaiyaCepheid Inc., Sunnyvale, California, USA.
Samarpita RoybardhanCepheid Inc., Sunnyvale, California, USA.
Ritu AnwesaCepheid Inc., Sunnyvale, California, USA.
Robert ReissDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Shawn WardFrontier Science Foundation, Brookline, Massachusetts, USA.
Adam Penn-NicholsonFoundation for Innovative New Diagnostics, Geneva, Switzerland.ORCID 0000-0002-1883-0059
Margaretha De VosFoundation for Innovative New Diagnostics, Geneva, Switzerland.ORCID 0000-0003-3059-2986
Derek T ArmstrongJohns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6223-4839
April L BorkmanMedical University of South Carolina, Charleston, South Carolina, USA.
Jerrold EllnerDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Susan E DormanMedical University of South Carolina, Charleston, South Carolina, USA.
Soyeon KimFrontier Science Foundation, Brookline, Massachusetts, USA.
Lin YuanCepheid Inc., Sunnyvale, California, USA.
David Alland *Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0001-5196-1571
Soumitesh Chakravorty *Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0001-5499-0204

Funding

FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
Cepheid Research grantNational Institute of Allergy and Infectious Diseases U01AI152084NIAID NIH HHS U01 AI152084
6 · The paper itself

Abstract

Tuberculosis (TB) is a global health threat complicated by increasing INH resistance (INH-R) and rifampicin resistance (RIF-R), including RIF-R due to IMPORTANCE: The Xpert MTB/RIF Ultra assay (Ultra) is a gold standard test for rapidly diagnosing tuberculosis (TB) as well as resistance to rifampicin directly from sputum samples. However, the Ultra assay does not detect certain rifampicin resistance mutations, which are observed clinically and cannot detect resistance to isoniazid, another key drug against TB. We modified the Ultra assay, creating a prototype MDRmDx assay designed for 10-color instruments that detects isoniazid resistance, which can be a precursor of potential rifampicin resistance and has improved ability to detect rifampicin resistance. In both analytic and retrospectively collected clinical sputum samples, we found that the MDRmDx assay performed at least as well as the Ultra assay with the additional advantage of detecting isoniazid resistance and

Indexed as

Drug Resistance, Multiple, BacterialMolecular Diagnostic TechniquesMycobacterium tuberculosisNucleic Acid Amplification TechniquesSputumTuberculosis, Multidrug-ResistantAntitubercular AgentsAutomation, LaboratoryBacterial ProteinsHumansLimit of DetectionRapid Diagnostic TestsRifampinSensitivity and SpecificityAntitubercular AgentsBacterial ProteinsRifampinmolecular diagnosticsmultidrug resistanttuberculosis

Identifiers

PMID41910325
PMCPMC13170168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.